Long-Term Treatment with Tenofovir in Asian-American Chronic Hepatitis B Patients Is Associated with Abnormal Renal Phosphate Handling (original) (raw)
Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS.. 2009;23:689–696. ArticleCASPubMed Google Scholar
Hall AM, Edwards SG, Lapsley M, et al. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis. 2009;54:1034–1042. ArticlePubMed Google Scholar
Hall AM, Hendry BH, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773–780. ArticleCASPubMed Google Scholar
Dauchy FA, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int. 2011;80:302–309. ArticleCASPubMed Google Scholar
Scherzer R, Estrella M, Li Y, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS.. 2012;26:867–875. ArticleCASPubMed CentralPubMed Google Scholar
Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS.. 2000;14:F63–F67. ArticleCASPubMed CentralPubMed Google Scholar
McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trial Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791–1801. ArticleCASPubMed CentralPubMed Google Scholar
Brim NM, Cu-Uvin S, Hu SL, O’Bell JW. Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome. AIDS Read.. 2007;17:322–328, C3. PubMed Google Scholar
Bonjoch A, Figueras M, Estany C, et al. Osteoporosis Study Group. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS.. 2010;24:2827–2833. ArticlePubMed Google Scholar
Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med.. 2009;10:482–487. ArticleCASPubMed Google Scholar
Jones S, Restrepo D, Kasowitz A, et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int. 2008;19:913–918. ArticleCASPubMed Google Scholar
Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49:1591–1601. ArticleCASPubMed Google Scholar
Perrot S, Aslangul E, Szwebel T, Caillat-Vigneron N, Le Jeunne C. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol.. 2009;15:72–74. ArticlePubMed Google Scholar
Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS.. 2012;26:825–831. ArticleCASPubMed Google Scholar
Haskelberg H, Hoy JF, Amin J, et al. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE. 2012;7:e38377. ArticleCASPubMed CentralPubMed Google Scholar
Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585. ArticlePubMed Google Scholar
Gish RG, Clark MD, Kane SD, Shaw RE, Mangahas MF, Baqai S. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B. Clin Gastroenterol Hepatol.. 2012;10:941–946. ArticlePubMed Google Scholar
Walton RJ, Bijvoet OLM. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975;2:309–310. ArticleCASPubMed Google Scholar
Stark H, Eisenstein B, Tieder M, Rachmel A, Alpert G. Direct measurement of TP/GFR: a simple and reliable parameter of renal phosphate handling. Nephron.. 1986;44:125–128. ArticleCASPubMed Google Scholar
Brodehl J, Krause A, Hoyer PF. Assessment of maximal tubular phosphate reabsorption: comparison of direct measurement with the nomogram of Bijvoet. Pediatr Nephrol. 1988;2:183–189. ArticleCASPubMed Google Scholar
Yenice N, Gümrah M, Mehtap O, Kozan A, Türkmen S. Assessment of bone metabolism and mineral density in chronic viral hepatitis. Turk J Gastroenterol.. 2006;17:260–266. PubMed Google Scholar
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1–129.
Rodriguez Novoa S, Garcia-Samaniego J, Calleja JL, et al. Altered underlying tubular function in HBV monoinfected patients receiving nucleos(t)ide analogs in a real-world setting: preliminary findings of MENTE study. Hepatology. 2013;58:676A.
Norden AG, Lapsley M, Unwin RJ. Urine retinol-binding protein 4: a functional biomarker of the proximal renal tubule. Adv Clin Chem. 2014;63:85–122. ArticleCASPubMed Google Scholar
Vigano M, Lampertico P, Mangia G, et al. Incidence and clinical consequences of reduced tubular phosphate reabsorption in naïve chronic hepatitis B patients either untreated or treated with tenofovir for 2 years in a field practice study. Hepatology. 2013;58:678A. Article Google Scholar
Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16:2205–2215. ArticleCASPubMed Google Scholar
Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2012;35:1317–1325. ArticleCASPubMed CentralPubMed Google Scholar
Gracey DM, Snelling P, McKenzie P, Strasser SI. Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther.. 2013;18:945–948. ArticlePubMed Google Scholar
Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol. 2011;55:1235–1240. ArticleCASPubMed Google Scholar
Martin M, Vanichseni S, Suntharasamai P, et al. Renal function of participants in the Bangkok Tenofovir Study-Thailand, 2005–2012. Clin Infect Dis. 2014; [Epub ahead of print].
Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, et al. Tenofovir nephrotoxicity: 2011 update. AIDS Res Treat.. 2011;2011:354908. PubMed CentralPubMed Google Scholar
Brown TT, Qaquish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS.. 2006;20:2165–2174. ArticlePubMed Google Scholar
Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS ONE. 2011;6:e23688. ArticleCASPubMed CentralPubMed Google Scholar
Schiefke I, Fach A, Wiedmann M, et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol. 2005;11:1843–1847. ArticleCASPubMed Google Scholar